抗菌治療市場按藥物類別、給藥途徑、適應症、分銷管道和地區分類

Antimicrobial Therapeutics Market, By Drug Class, By Route of Administration, By Disease Indication, By Distribution Channel, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

抗菌治療市場規模預計在 2025 年達到 1,228.9 億美元，預計到 2032 年將達到 1,799.6 億美元，2025 年至 2032 年的年複合成長率為 5.6%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	1228.9億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年年複合成長率：	5.60%	2032年價值預測	1799.6億美元

抗生素是用來殺死細菌或使其難以在人體或動物體內生長的藥物。它們通常用於治療嚴重感染疾病，例如肺炎和血流感染疾病(BSI)。抗生素可以口服，形式為錠劑、錠劑或液體。對於更嚴重的感染疾病，它們也可以注射或直接注射到血液（靜脈內）。它們也可以作為乳膏、噴霧劑或軟膏塗抹在皮膚上。如果使用不當，抗生素會引起嚴重的副作用，並導致抗藥性細菌的產生。這種抗藥性使得使用相同的藥物甚至使用對抗抗藥性細菌有效的其他藥物來治療感染疾病變得困難。抗生素是用於治療由細菌、病毒、真菌和寄生蟲等微生物引起的感染疾病的藥物。這些藥物透過殺死或抑制微生物的生長來發揮作用。然而，這些藥物的濫用和過度使用導致了抗菌素抗藥性的出現，這已成為一個重大的全球健康問題。由於感染疾病的盛行率不斷上升、新藥的開發以及對抗菌素抗藥性意識的不斷提高，全球抗菌市場預計將繼續成長。

市場動態：

預計在預測期內，監管產品認證的增加將推動市場成長。例如，製藥公司Zydus Lifesciences宣布，已獲得美國食品藥物管理局（FDA）的最終核准，可以銷售用於治療某些類型真菌或酵母菌感染疾病的抗真菌藥物物Micafungin。

本研究的主要特點

本報告對全球抗菌治療市場進行了詳細分析，並以 2024 年為基準年，給出了預測期 2025-2032 的市場規模和年複合成長率（CAGR%）。
它強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球抗菌治療市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球抗菌治療市場的各種策略矩陣來促進他們的決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 122.89 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.60%	2032 Value Projection:	USD 179.96 Bn

Antimicrobial therapeutics are medicines that kill or make it harder for bacteria to grow and multiply in people or animals. They are often used to treat serious infections, such as pneumonia or bloodstream infections (BSIs). Antibiotics can be taken by mouth in the form of pills, tablets, or liquids. They can also be injected or given directly into the bloodstream (IV) for more severe infections. They can also be applied to the skin as a cream, spray, or ointment. When used incorrectly, antibiotics can cause serious side effects and lead to resistant microorganisms. This resistance makes it harder to treat infections with the same medicine or even other medicines that are effective against them. Antimicrobial therapeutics are medications used to treat infections caused by microorganisms, including bacteria, viruses, fungi, and parasites. These therapeutics work by either killing the microorganisms or inhibiting their growth. However, the misuse and overuse of these drugs have led to the emergence of antimicrobial resistance, which is a significant global health concern. The global antimicrobial therapeutics market is expected to grow due to the increasing prevalence of infectious diseases, the development of new drugs, and the growing awareness of antimicrobial resistance.

Market Dynamics:

Increasing product approval by regulatory bodies is expected to drive the growth of the market over the forecast period. For instance, Zydus Lifesciences, a pharmaceutical company, announced that it had received final approval from the U.S. Food and Drug Administration (FDA) to market its antifungal medicine Micafungin, which is used to treat certain types of fungal or yeast infections.

Key features of the study:

This report provides in-depth analysis of the global antimicrobial therapeutics market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antimicrobial therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche AG, AstraZeneca plc, Sanofi SA, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., AbbVie Inc., Allergan plc, Mylan N.V. and Alembic Pharmaceuticals Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antimicrobial therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antimicrobial therapeutics market

Detailed Segmentation:

Global Antimicrobial Therapeutics Market, By Drug Class:
- Antibacterials
- Antivirals
- Antifungals
- Antiparasitics
Global Antimicrobial Therapeutics Market, By Route of Administration:
- Oral
- Topical
- Injectable
- Others
Global Antimicrobial Therapeutics Market, By Disease Indication:
- Respiratory Infections
- Urinary Tract Infections (UTIs)
- Skin and Soft Tissue Infections
- Sexually Transmitted Infections (STIs)
- Gastrointestinal Infections
- Central Nervous System Infections
- Others
Global Antimicrobial Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Antimicrobial Therapeutics Market, By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profile:
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- F. Hoffmann-La Roche AG
- AstraZeneca plc
- Sanofi SA
- Bayer AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences, Inc.
- AbbVie Inc.
- Allergan plc
- Mylan N.V.
- Alembic Pharmaceuticals Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Antimicrobial Therapeutics, By Drug Class
- Market Antimicrobial Therapeutics, By Route of Administration
- Market Antimicrobial Therapeutics, By Disease Indication
- Market Antimicrobial Therapeutics, By Distribution Channel
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Antimicrobial Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Antimicrobial Therapeutics Market, By Drug Class, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Antibacterials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Antifungals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Antiparasitics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Antimicrobial Therapeutics Market, By Route of Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Antimicrobial Therapeutics Market, By Disease Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Respiratory Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Urinary Tract Infections (UTIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Skin and Soft Tissue Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Sexually Transmitted Infections (STIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Gastrointestinal Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Central Nervous System Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Antimicrobial Therapeutics Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Antimicrobial Therapeutics Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn )
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn )
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn )
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country,2020 - 2032, (US$ Bn )
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn )
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2020 - 2032, (US$ Bn )
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Allergan plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Alembic Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views